Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- After GCP Scandal, Medipharma Begins Bankruptcy Proceedings
January 5, 2024
- Astellas, China Biotech Hook Up on Bispecific Macrophage Engagers
January 5, 2024
- South Korean Partner to Locally Manufacture Xocova: Shionogi
December 28, 2023
- Healios, Nobelpharma Ink Basic Deal for Cell Therapy Alliance in ARDS
December 28, 2023
- Amylyx Gears Up to Bring New ALS Drug to Japan Market: Country Chief
December 27, 2023
- Eisai, Oita University Develop Wearable Sensor to Predict Brain Aβ Buildup
December 27, 2023
- iPSC-Based Parkinson’s Therapy Cleared for Investigator-Led Trial in US: Sumitomo
December 27, 2023
- Daiichi’s HER3 ADC Gets Priority Review in US for 3rd Line EGFR-Mutated NSCLC
December 26, 2023
- Mochida Files Label Expansion for Inhaled Treprost in Japan
December 26, 2023
- Sandoz to Take Over Distribution Rights to Japan’s 1st Humira Biosimilar
December 26, 2023
- Manabu Chikumoto to Helm Mitsubishi Chemical Group from April
December 25, 2023
- Rune Ejler Andersen Tapped as Japan Chief of Lundbeck
December 25, 2023
- Astellas Closes Buyout of US Prostate Cancer Drug Maker Propella
December 25, 2023
- Meiji’s Kostaive Booster Dose Non-Inferior to Pfizer COVID Jab: PIII Data
December 25, 2023
- Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 22, 2023
- Mitsubishi Tanabe Sells Entire Stake in China JV to Local Firm
December 22, 2023
- Nippon Shinyaku’s DMD Med Snags Orphan Status in Europe
December 22, 2023
- Ono, UK DRI to Partner in Dementia Drug Discovery Research
December 21, 2023
- Maruishi Gains Japan Rights to Allay’s Postoperative Pain Relief Drug
December 21, 2023
- JCR, Alexion Tie Up to Develop Oligonucleotide Therapeutics
December 21, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…